Introduction
Human African trypanosomiasis (HAT ‡ or sleeping sickness), a neglected tropical disease caused by subspecies of the protozoan parasite Trypanosoma brucei, is endemic in several regions of sub-Saharian Africa. It also represents a serious economic and social burden to some of Africa's poorest countries. 1 According to the last epidemiologic update by the World Health Organization (WHO), 2 50000 to 70000 people were infected in 2006. However, this may remain only a short-term view as no long-term systematic screening of the population at risk is currently ongoing. 3 Chemotherapy of HAT relies on four old drugs (suramin, pentamidine, melarsoprol and eflornithine) which have unacceptable toxicity and require parenteral administration.
This, greatly complicates the treatment of patients in disease endemic countries with no basic health care systems. 4, 5 The treatment options available for the late-stage disease involving central nervous system (CNS) infection are particularly deficient as they mostly rely on a highly toxic arsenical derivative, melarsoprol, which provokes deadly post-treatment reactive encephalopathy in up to 10% of the cases. 4 Even though the recent inclusion of the combination therapy Nifurtimox-eflornithine as simplified stage 2 treatment for T. b. gambiense sleeping sickness improves the therapeutic arsenal against late-stage HAT, the discovery of new orally active drugs that are able to cure the acute and CNS stages of HAT remains a priority in tropical medicine.
1
In previous reports, we have shown that 4,4'-bis(imidazolinylamino)diphenylamine dihydrochloride (1, Chart 1) displayed excellent antitrypanosomal 6 and antiplasmodial activity in vitro. The crystal structure of 1 bound to its preferred DNA binding site 5'-AATT has suggested a basis for understanding the antitrypanosomal action of this compound. 8 Further studies in vivo have shown that this trypanocidal lead compound was curative by intraperitoneal administration in murine models of acute T. b. brucei and T. b. rhodesiense infections, but not in the late-stage disease involving CNS infection. 9 A reason for the lack of effectiveness against the CNS-stage is a poor brain penetration that is most likely due to the positively charged imidazolinylamino groups (pK a = 9.9) 10 at physiological pH, which limit its passage through the blood-brain barrier (BBB). The same drawback has been observed with diamidine drugs such as pentamidine or diminazene which have been used for decades as a first line treatment for early stage gambiense sleeping sickness and cattle trypanosomiasis (Nagana),
respectively. Previous reports in the literature have shown that derivatization of the amidine group as amidoxime prodrug was useful to overcome this problem and improve the oral bioavailibility and CNS delivery of diamidines. These amidoxime prodrugs are metabolized to the amidine active compounds through sequential oxidative Odemethylation by cytochrome P450 isoforms 1A1, 1A2 and 1B1 and cytochrome b5 catalyzed reductive N-dehydroxylation reactions. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] More recently, similar prodrug strategies (e.g., N-substituted bis-Calkyloxadiazolones, 22 N,N'-dihydroxyamidines, 23 O-carboxymethylamidoximes, 24 diacetyldiamidoximeester 25 ) for the oral delivery of amidines and guanidines were also reported.
In line with these findings, we have developed a similar approach (i.e., synthesis of Nalkoxy analogues) to reduce the pK a of the imidazolinylamino moiety in order to improve the pharmacokinetics of compound 1. We also sought to establish the influence of replacing the imidazolylamino moiety with a closely related heterocycle (i.e., 4,5-dihydrothiazolinylamine) that has lower pK a value so as to avoid problems of being ionized at physiological pH (i.e., the pK a of thiazolines is ca. 3 units lower than the pK a of imidazolines; e.g., 2-aminoimidazole: pK a = 8.46; 26 2-aminothiazole, pK a = 5.39). 27 Hence, five different N-alkoxy substituted analogues of 1 (Chart 1) and the 4,5-dihydrothiazolinylamino derivative 17 (Scheme 2) were synthesized. The antitrypanosomal activity of the target compounds was checked in vitro against the STIB900 Trypanosoma brucei rhodesiense strain. As additional data, we also checked the antiprotozoal activity of the new compounds against 3 related parasites (Trypanosoma cruzi, Leishmania donovani and Plasmodium falciparum).
Further, the activity of the new compounds was assayed in vivo in the murine model of acute T. brucei infection. Additionally, the BBB permeability of the compounds was determined in vitro by permeability assays through the hCMEC/D3 human endothelial cell monolayer. 28, 29 This cell line holds most of the specific properties of in vivo BBB, 
Results
Chemistry. We attempted two different synthetic strategies in order to obtain the Nalkoxy-substituted derivatives of 1. Both approaches relied on the reaction of two equivalents of a functionalized ethylenediamine precursor (4-5, or 9) with the isothiocyanate 3, previously prepared in 80% yield from 4,4'-diaminodiphenylamine (Scheme 1). 32 The thiourea intermediates obtained (6-7, and 10-11, respectively) were subsequently subjected to intramolecular cyclization after adequate removal of the amine protecting groups. Regarding the first synthetic strategy, the N-alkoxyethylenediamine precursors 4, 5a,
and 5b were prepared in low yield following the protocol previously described for compound 4 (Equation 1). The reaction of 3 with 2.5 equivalents of 4, or 5a, gave 6 and 7, respectively (Scheme 1). Attempts to optimize the conditions for the deprotection of the amino groups with hydrazine/EtOH and the subsequent in situ cyclization to the target compound 14 were disappointing, leading to several by-products. Hence, the thiourea 6 was activated via formation of the methylisothiouronium salt 8, which was obtained almost quantitatively (excess CH 3 I/ CH 2 Cl 2 / rt / 24h) with a purity > 80%. Partial deprotection of one benzyl group accounted for the lower purity of the product. Longer reaction times slightly increased the yield of the deprotection product. Attempts of purification by chromatography were unsuccessful so the compound was used in the cyclization step without further purification. The deprotection of the amino groups (MeNH 2 / THF-H 2 O) and the consequent in situ spontaneous cyclization afforded 14, which was isolated in 40% yield after silica chromatography. Our attempts to scale up the synthesis of 5a and 5b were unsuccessful so we explored a different strategy to obtain the corresponding methoxy 12 and ethoxy analogues 13. As an alternative, we considered the deprotection of the benzyl protecting groups of 14 and the subsequent alkylation of 16 to the corresponding alkoxy derivatives. However, all of the attempts to remove the benzyl groups, either by catalytic hydrogenolysis or by other classical methods, 35 b. rhodesiense and 270-fold against P. falciparum) confirmed these findings. The higher pK a of the imidazoline structure (pK a = 9.9 for 1 10 ) ensures a higher proportion of the ionized form of the molecule at physiological pH, which proved important for high activity in this series.
None of the new compounds showed significant activity against axenically grown amastigotes of L. donovani. On the contrary, one compound, 14, presented an IC 50 value 3-times higher than the reference drug benznidazole (1.64 µM) on intracellular T. cruzi amastigotes. The synthetic intermediates (urea derivatives) 6, 7, 10a, and 11b were poorly active on the four parasites with IC 50 in the high micromolar range (Table 1) . Rat skeletal myoblast L-6 cells; g Data taken from ref. [6, 7] . h Not available. See reference [37] for detailed experimental procedures.
In Vivo Antitrypanosomal Activity. In the T. b. rhodesiense STIB900 mouse model of acute infection, which mimics the first stage of the disease, the lead compound 1 was curative when administered intraperitoneally at 4×20 mg/kg. 9 However, it was hardly effective by oral route in this model (i.e., 10% increase in mean relapse days compared to control, no cures), and totally inactive in the GVR35 mouse model that mimics the late stage of the disease involving CNS infection. 9 The newly synthesized N-alkoxy analogues of 1 were designed as possible prodrugs with improved oral bioavailability and enhanced CNS uptake. In order to check their in vivo activity, compounds 12-16
were administered by intraperitoneal (4×20 mg/kg) and oral route (4×50 mg/kg) to T.
brucei infected mice (Table 2) Compounds 1, 12, 13, and 16 did not affect the endothelial monolayer integrity (i.e., a low permeability to LY was conserved) at concentrations of 100 µM whereas 14 required a concentration of 10 µM (Figure 1 ). Compound 14, at this concentration, made the analysis of the results unreliable (i.e., beyond the sensitivity limits of our HPLC detection method). This suggests a very low permeability through the in vitro BBB for this compound.
The measured permeability values for the lead compound (1), the O-methoxy (12), and O-ethoxy (13) derivatives were not significantly different from the one measured for the poorly permeable compound LY. In contrast, the 1-hydroxy analogue (16) had significant higher permeability than LY and also than compound 1 (nearly 3-fold).
These results show that N-substitution of the imidazolylamino group with OH enhances the in vitro BBB permeability of this molecule whereas O-alkyl substituents do not improve the in vitro BBB permeability.
Lucifer yellow permeability showing the same drawback as the above mentioned diamidines.
As expected for a prodrug requiring in vivo metabolic activation, the N-alkoxy derivatives displayed reduced activity (in the submicromolar range) in the parasite susceptibility assay in vitro. Furthermore, one of the new N-alkoxy derivatives, 16, was active in vivo in the STIB900 mouse model after intraperitoneal administration. Even though this moderate effect could be attributed to the fair intrinsic activity observed in vitro for this compound (IC 50 = 0.37 µM), it is likely due to a partial bioactivation of 16
to the lead compound 1. In fact, the 2-aminoimidazolinyl moiety can be viewed as a cyclic guanidine 42 and the in vivo reduction of N-hydroxylated guanidines and amidines by microsomes and mitochondria of different organs from different species (e.g., kidney, liver, brain) has been established before. 12, 43, 44 This result is important because it is compound 16 that showed the highest in vitro BBB permeability in our assays. The respectively), may possibly be attributed to a poor bioactivation. As far as we know, the bioactivation of N-alkoxy prodrugs has been described for amidines but not for guanidines.On the other hand, this might be explained by a high fraction of protein binding or other unfavourable pharmacokinetics.
The P e values measured in vitro with the human brain endothelial cell line hCMEC/D3
for the lead compound 1, and the O-alkyl substituted derivatives 12 and 13, were comparable to the P e values of the control molecule LY that presents a very low brain uptake (see experimental section for more details). Thus, compound 1 scarcely penetrates the BBB which possibly explains why this molecule is inactive in the murine model of late-stage HAT. 9 The derivatization of the imidazoline nitrogen with OMe or
OEt did not improve the BBB permeability whereas a free OH group increased the permeability by almost 3-fold compared with the lead compound 1. In comparison, the benzodiazepine drug diazepam that is used as anxiolytic and has large BBB uptake 45 shows 10-fold higher permeability than LY using the hCMEC/D3 cell line (data not shown). This means that compound 16 shows an intermediate in vitro permeability to the brain.
This result was somewhat unexpected as increasing the number of hydrogen bond donors and the polar surface area is generally associated with a reduced BBB permeability. 46 To try rationalize these results, we calculated some physicochemical parameters that are generally accepted as important for a compound to be readily BBB permeable (Table 3) . 47 The molecular hydrophobicity of a compound, measured as the octanol/water partition coefficient (logP), is an important physicochemical property associated with biological membrane permeation. For ionizable molecules to be BBB permeable, values of octanol/water distribution coefficients, logD 7.4 , in the range between 1 and 3 are recommended. 48 As shown in Table 3 , two compounds only, 12
and 16, have logD 7.4 values within this range. Thus, adequate hydrophobicity and low pK a values may explain the enhanced in vitro BBB permeability observed for 16.
However, these data do not explain the low permeability of 12 measured in vitro. Taken togrether, these findings show that subtle modification of the nitrogen substituent (e.g., OH ↔ OMe) greatly affects the BBB permeability of the bis-2-imidazolinylamino compounds. 
Conclusions
Several N-alkoxy analogues of compound 1 were designed to reduce the basicity of the aminomidazolinyl groups and potentially improve the oral and CNS absorption of that trypanocidal lead compound. Four of these derivatives showed submicromolar IC 50 values in vitro against T. brucei and P. falciparum, but only one compound, the Nhydroxy-2-imidazolylamino analogue 16, displayed moderate activity in vivo in the T. brucei STIB900 murine model at a dosage of 20mg/kg ip. This modest activity is possibly due to an incomplete bioactivation of the prodrug in vivo that does not permit to reach the curative dose of the active compound. Even though other pharmacokinetic aspects such as plasma protein binding cannot be ruled out at this time, the in vivo activity displayed by 16 means that a substantial fraction of the active compound is unbound and free to reach its target in vivo. Further work to fully understand the pharmacokinetics of these compounds will be needed but this shall be the subject of a different study.
More importantly, this compound also had the highest BBB permeability of the series (i.e., almost 3-fold increase with respect to lucifer yellow) in the in vitro transport assay involving the human brain endothelial cell line hCMEC/D3. These results suggest that N-hydroxy-2-imidazolylamino analogues may possibly be used as prodrugs of the imidazolylamino group with enhanced BBB penetration. Efforts are ongoing towards the discovery of more potent drugs able to cross the BBB for the treatment of late-stage HAT.
Experimental section
Chemistry. All dry solvents were purchased from Aldrich (Sigma-Aldrich Quimica (14) and 1-tetrahydropyranyloxy-(15) derivatives were synthesised following the one-pot procedure previously reported by us. The products showed satisfactory spectroscopic and analytical data as reported previously. 36 In separate experiments, the thiourea intermediates (10a and 10b) were also isolated and fully characterized. The spectroscopic data are given below.
N,N'-(2,2'-(4,4'-Azanediylbis(4,1-phenylene)bis(azanediyl))bis(thioxomethylene)bis (azanediyl)bis(ethane-2,1-diyl))bis(N-methoxy-2-nitrobenzenesulfonamide) (10a).
A solution of isothiocyanate 3 (0.30 mmol, 85 mg, 1 equiv.) in dry DMF (1 mL) was added to a solution of N-(2-aminoethyl)-N-methoxy-2-nitrobenzenesulfonamide (9, R 1 = Me) 36 (0.60 mmol, 277 mg, 2 equiv.) in dry DMF (5 mL). The resulting mixture was stirred at room temperature for 2 days. Water was added to give a precipitate that was In summary, endothelial cells were cultured in Boyden chamber-like system allowing them to separate 2 compartments, the upper or luminal compartment and the lower or abluminal one, which represent the blood and the cerebral one, respectively.
Permeability assays. Prior compound permeability study, it is essential to find a working concentration of the compounds that will not disturb the cellular complex between endothelial cells. For this purpose, endothelial monolayer quality was checked by following the passage of the small hydrophilic fluorescent molecule lucifer yellow (LY, Sigma, St Louis, MO, USA) when a fixed concentration of the studied compound (i.e., 12, 13, 14, or 16) was put on the cells in the luminal compartment. Note that LY is widely used and accepted as a marker of tight junction integrity. 40 If LY permeability was affected by the presence of the compound, the concentration of the compound was decreased until a non-affecting dose was reached.
Compound 1 was directly dissolved in transport buffer whereas the N-alkoxy derivatives ( Endothelial permeability was calculated from the clearance rate and the surface area, as previously described. 38, 39 In this way, a concentration-independent permeability value was obtained. The increment in cleared volume between successive sampling events is calculated by dividing the amount of solute during the interval time by the donor chamber concentration, which is the luminal one in this study, as described below:
The total cleared volume at each time point is calculated by summing the incremental cleared volumes up to the given time point:
Where X is the amount of drug in the receptor chamber (the abluminal one) and C d is the donor chamber concentration at each time-point. The average volume cleared is plotted versus time, and the slope estimated by linear regression analysis, which allows calculating total endothelial monolayer permeability noted PS e :
1 / PS e = 1 / PS t -1 / PS f and P e = PS e / A,
where PS e is the permeablitiy-surface area product value for the endothelial cell monolayer, A is the surface area of the filter (in cm 2 ), PS t and PS f are the slopes of the clearance curves for the cell monolayer on coated culture insert filter and for the coated culture insert filter alone (meaning without cell monolayer), respectively. The PS e values are divided by the surface area (A, in cm 2 ) of the culture insert to generate the endothelial permeability coefficient (P e , in cm per min). These P e values allow classifying the molecules into 3 categories: low-, intermediate-or high-brain uptake.
Compound permeability values were expressed as an increase or decrease compared with a model of low brain uptake, LY permeability (P e = 3.04 × 10 -3 cm/min), which is given the value of 100%. LY was chosen as paracellular diffusion marker because of its properties: it is a small (457.3 Da) and hydrophilic molecule that has no transporter on endothelial cells (data not shown).
HPLC analysis of the results. 1 mL samples for each time point were taken directly from the basal compartment and transferred to 1.5 mL Waters HPLC vials that were stored in the freezer. The samples were defrost and shaken with an orbital shaker for 20 min just before running the HPLC analysis. Analytical HPLC-MS was run with a coupled with a Waters Micromass ZQ spectrometer using electrospray ionization (ES + ).
The following HPLC conditions were used: column temperature = 30 ºC, flow rate = 1 mL/min, gradient time = 5 min, the solvent mixture was H rhodesiense strain STIB900, amastigotes of L. donovani strain MHOM/ET/67/L82, and cytotoxicity on rat myoblasts L-6 cells were determined using the Alamar blue assay. Nonidet. 53 Detailed experimental protocols for all of these assays have been reported before. human BBB R = OH 3-f old increase P e
